SEROTONIN-INDUCED CONTRACTION IN CANINE CORONARY-ARTERY AND SAPHENOUS-VEIN - ROLE OF A 5-HT1D-LIKE RECEPTOR

被引:26
作者
CUSHING, DJ [1 ]
BAEZ, M [1 ]
KURSAR, JD [1 ]
SCHENCK, K [1 ]
COHEN, ML [1 ]
机构
[1] LILLY CORP CTR,LILLY RES LABS,DEPT CARDIOVASC PHARMACOL,INDIANAPOLIS,IN 46285
关键词
SEROTONIN; VASCULAR SMOOTH MUSCLE; CORONARY ARTERY; SAPHENOUS VEIN;
D O I
10.1016/0024-3205(94)00607-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The identity of the serotonin (5-HT) receptors(s) that mediate(s) contraction in canine coronary artery and saphenous vein remains controversial. Ring segments of endothelium-denuded coronary artery and helical strips of saphenous vein were suspended in organ chambers for measurement of isometric force. 5-HT, alpha Me-5-HT and sumatriptan contracted both coronary artery and saphenous vein and the non-selective 5-HT receptor antagonist 1-naphthylpiperazine (100nM) blocked 5-HT- and sumatriptan-induced contraction in both tissues. The agonist rank order potency for contraction (5-HT>sumatriptan>alpha Me5-HT>MeOT>5-MeT) was similar in both tissues and was consistent with that for a 5-HT1D receptor. Oligonucleotide primers specific for the 5-HT1D receptor sequence was designed for use in a polymerase chain reaction (PCR). cDNA derived from total RNA or mRNA from canine tissues was used in the PCR. PCR resulted in the amplification of a 632 base pair sequence in both canine coronary artery and saphenous vein; consistent with that expected for the 5-HT1D receptor. Southern blot analysis, with an oligonucleotide probe internal to the sequence amplified by the PCR primers, confirmed that the sequence amplified by PCR with the 5-HT1D receptor. Thus, the 5-HT1D receptor is expressed in canine coronary artery and saphenous vein and taken together with the pharmacological data, supports the possibility that a 5-HT1D-like receptor mediates contraction in these two tissues.
引用
收藏
页码:1671 / 1680
页数:10
相关论文
共 26 条
[1]   ANTIMIGRAINE DRUG SUMATRIPTAN INCREASES BLOOD-FLOW VELOCITY IN LARGE CEREBRAL-ARTERIES DURING MIGRAINE ATTACKS [J].
CAEKEBEKE, JFV ;
FERRARI, MD ;
ZWETSLOOT, CP ;
JANSEN, J ;
SAXENA, PR .
NEUROLOGY, 1992, 42 (08) :1522-1526
[2]   5-HYDROXYTRYPTAMINE RECEPTOR PROFILE IN HEALTHY AND DISEASED HUMAN EPICARDIAL CORONARY-ARTERIES [J].
CHESTER, AH ;
MARTIN, GR ;
BODELSSON, M ;
ARNEKLONOBIN, B ;
TADJKARIMI, S ;
TORNEBRANDT, K ;
YACOUB, MH .
CARDIOVASCULAR RESEARCH, 1990, 24 (11) :932-937
[3]   INTERACTION BETWEEN THROMBOXANE-A2 AND 5-HYDROXYTRYPTAMINE RECEPTOR SUBTYPES IN HUMAN CORONARY-ARTERIES [J].
CHESTER, AH ;
ALLEN, SP ;
TADJKARIMI, S ;
YACOUB, MH .
CIRCULATION, 1993, 87 (03) :874-880
[4]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[5]   SUMATRIPTAN AND 5-BENZYLOXYTRYPTAMINE - CONTRACTILITY OF 2 5-HT(1D) RECEPTOR LIGANDS IN CANINE SAPHENOUS VEINS [J].
COHEN, ML ;
SCHENCK, K ;
NELSON, D ;
ROBERTSON, DW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 211 (01) :43-46
[6]  
COHEN RA, 1986, J PHARMACOL EXP THER, V237, P548
[7]   5-HYDROXYTRYPTAMINE CONTRACTS HUMAN CORONARY-ARTERIES PREDOMINANTLY VIA 5-HT2 RECEPTOR ACTIVATION [J].
CONNOR, HE ;
FENIUK, W ;
HUMPHREY, PPA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 161 (01) :91-94
[8]  
CUSHING DJ, 1992, J PHARMACOL EXP THER, V263, P123
[9]  
CUSHING DJ, 1992, J PHARMACOL EXP THER, V261, P856
[10]   DIVERGENT EFFECTS OF SEROTONIN ON CORONARY-ARTERY DIMENSIONS AND BLOOD-FLOW IN PATIENTS WITH CORONARY ATHEROSCLEROSIS AND CONTROL PATIENTS [J].
GOLINO, P ;
PISCIONE, F ;
WILLERSON, JT ;
CAPPELLIBIGAZZI, M ;
FOCACCIO, A ;
VILLARI, B ;
INDOLFI, C ;
RUSSOLILLO, E ;
CONDORELLI, M ;
CHIARIELLO, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (10) :641-648